SNOA vs PRPH vs QDEL vs SSKN vs HSIC

For growth investors, Sonoma Pharmaceuticals, Inc.

(SNOA) is the stronger pick with 12. 2% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate QuidelOrtho Corporation (QDEL) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, QuidelOrtho Corporation is actually cheaper at 6.

0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Henry Schein, Inc.

(HSIC) delivered a total return of -14. 6%, compared to -99. 2% for Sonoma Pharmaceuticals, Inc. (SNOA). Over 10 years, the gap is even starker: PRPH returned +38. 1% versus SNOA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 38β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately -696% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Sonoma Pharmaceuticals, Inc. (SNOA) carries a lower debt/equity ratio of 7% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sonoma Pharmaceuticals, Inc.

(SNOA) is pulling ahead at 12. 2% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Sonoma Pharmaceuticals, Inc. grew EPS 47. 6% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, SNOA leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — SSKN leads at 56. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

0x forward P/E versus 13. 2x for Henry Schein, Inc. — 7. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HSIC: 20. 6% to $85. 43.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.